OBJECTIVE: Primary and secondary syphilis rates in the US are rising and congenital syphilis reports to CDC have increased 87% since 2012. Many hospital laboratories have switched to the reverse algorithm for syphilis testing with an automated treponemal screening test (syphilis enzyme immunoassay (EIA) or IgG) instead of a nontreponemal screen (RPR). Our goal was to compare performance characteristics of the traditional and reverse algorithms for syphilis testing in pregnancy. STUDY DESIGN: This retrospective cohort analysis included pregnant women tested for syphilis who delivered at our center between 11/ 2012 and 12/2017. The cohort was separated into two groups based on the lab algorithm switch date: "traditional algorithm" (11/2012-10/2014) and "reverse algorithm" (11/2014-12/2017). The treponemal screening test for the reverse algorithm was EIA (Trinity). Non-treponemal testing used RPR and follow-up treponemal testing used the T. pallidum particle agglutination assay (TPPA). Algorithm cohorts were compared for rates of screen positivity. RESULTS: Serologic testing for syphilis was performed at our institution for 8,790 pregnant women using the traditional algorithm and 11,403 women with the reverse algorithm. Maternal age, race, marital status, and location of testing (outpatient vs. inpatient) were similar for both groups: approximately 50% of women were Black and 80% were tested as outpatients. Under the traditional algorithm, 0.5% (95% CI 0.4-0.7%) (46/8790) were RPR screen +, and 50% (18/36) of those with reflex testing were TPPA+ (0.25% true infection). (Fig 1) Under the reverse algorithm, 0.7% (95% CI 0.6-0.9%) (83/11403) were EIA screen +, and 30% (25/83) were RPR+ (0.21% true infection). Screen positivity was similar in both groups (p¼0.08). In the reverse algorithm, only 41.4% (24/58) of EIA+/ RPR-samples had confirmatory TPPA testing, but 33.3% (8/24) were TPPA negative (EIA+/RPR-/TPPA-), indicating EIA false positivity. (Fig 2) CONCLUSION: In a diverse US region with high STI prevalence, the traditional and reverse syphilis testing algorithms in pregnancy have similar rates of screen positivity. Use of the reverse algorithm may be limited by an elevated proportion of discordant results (EIA+/RPR-) that require additional testing and can reflect previously treated infection. False-positive screens are a limitation of both algorithms and new strategies to detect active syphilis in pregnancy are needed. OBJECTIVE: Universal screening for chlamydia infection in pregnancy is recommended by ACOG to prevent adverse birth outcomes. Chlamydia trachomatis (CT) is an intracellular bacteria that can lead to persistent or recurrent infection despite therapy in 7-15% of nonpregnant women. Since data in pregnancy is minimal, we sought to determine rates of persistent/recurrent CT infection in this group. STUDY DESIGN: We performed a retrospective cohort analysis of women with deliveries at our center between 11/2012 e 12/2017. Testing was performed with highly sensitive nucleic acid amplification (Roche and Aptima Hologic) on samples from genital swabs or Poster Session III ajog.org
OBJECTIVE: Primary and secondary syphilis rates in the US are rising and congenital syphilis reports to CDC have increased 87% since 2012. Many hospital laboratories have switched to the reverse algorithm for syphilis testing with an automated treponemal screening test (syphilis enzyme immunoassay (EIA) or IgG) instead of a nontreponemal screen (RPR). Our goal was to compare performance characteristics of the traditional and reverse algorithms for syphilis testing in pregnancy. STUDY DESIGN: This retrospective cohort analysis included pregnant women tested for syphilis who delivered at our center between 11/ 2012 and 12/2017. The cohort was separated into two groups based on the lab algorithm switch date: "traditional algorithm" (11/2012-10/2014) and "reverse algorithm" (11/2014-12/2017 ). The treponemal screening test for the reverse algorithm was EIA (Trinity). Non-treponemal testing used RPR and follow-up treponemal testing used the T. pallidum particle agglutination assay (TPPA). Algorithm cohorts were compared for rates of screen positivity. RESULTS: Serologic testing for syphilis was performed at our institution for 8,790 pregnant women using the traditional algorithm and 11,403 women with the reverse algorithm. Maternal age, race, marital status, and location of testing (outpatient vs. inpatient) were similar for both groups: approximately 50% of women were Black and 80% were tested as outpatients. Under the traditional algorithm, 0.5% (95% CI 0.4-0.7%) (46/8790) were RPR screen +, and 50% (18/36) of those with reflex testing were TPPA+ (0.25% true infection). (Fig 1) Under the reverse algorithm, 0.7% (95% CI 0.6-0.9%) (83/11403) were EIA screen +, and 30% (25/83) were RPR+ (0.21% true infection). Screen positivity was similar in both groups (p¼0.08). In the reverse algorithm, only 41.4% (24/58) of EIA+/ RPR-samples had confirmatory TPPA testing, but 33.3% (8/24) were TPPA negative (EIA+/RPR-/TPPA-), indicating EIA false positivity. (Fig 2) CONCLUSION: In a diverse US region with high STI prevalence, the traditional and reverse syphilis testing algorithms in pregnancy have similar rates of screen positivity. Use of the reverse algorithm may be limited by an elevated proportion of discordant results (EIA+/RPR-) that require additional testing and can reflect previously treated infection. False-positive screens are a limitation of both algorithms and new strategies to detect active syphilis in pregnancy are needed. OBJECTIVE: Prophylaxis starting at 36 weeks has been shown to reduce the rate of cesarean delivery (CD) in patients with a history of recurrent herpes simplex virus (HSV). However, guidelines do not differentiate between patients who are planning a scheduled CD at term and those who are planning to labor. The objective of this study was to examine whether HSV prophylaxis in patients planning to deliver by CD is cost-effective. STUDY DESIGN: This was a cost-effectiveness analysis from the societal perspective comparing antiviral prophylaxis to no treatment in patients with a history of recurrent HSV planning to deliver by CD. Costs in 2018 US $, utilities, and probabilities were derived from the literature. We assumed that 96.7% of patients planning on CD would deliver by CD, and that CD would reduce the rate of neonatal HSV by 85% compared to vaginal delivery (VD). We included asymptomatic shedding in the model because this is associated with neonatal HSV. We modeled neonatal outcomes including no HSV, central nervous system HSV, and skin, eyes, and mouth HSV, and included hospital costs for neonates (including neonatal screening in cases of maternal outbreak but asymptomatic neonate) as well as education or institutional costs and future health care costs up to age 20. Utilities were measured in qualityadjusted life years (QALY) assuming a life expectancy of 20 years for severe disability and 78.8 years for all other neonates. Costs and QALYs were discounted 3%, and the willingness-to-pay (WTP) threshold was $100,000/QALY. Deterministic 1-way sensitivity analyses were performed. RESULTS: Prophylaxis reduced expected costs by $241, increased QALYs by 0.0045, and reduced the incidence of neonatal HSV from 83/100,000 to 25/100,000. Although prophylaxis became the more costly strategy at a drug cost of $256, at the WTP prophylaxis remained cost-effective until the drug cost was > $703. The model was not sensitive to the rate of CD or the reduction in HSV from CD versus VD. If prophylaxis reduced the rate of neonatal HSV by <2%, then it would no longer be cost-effective. CONCLUSION: Despite the relative rarity of neonatal HSV in offspring of patients with a history of recurrent HSV, prophylaxis in patients planning on CD is cost-effective across a wide range of assumptions. Notably, prophylaxis has never been shown in trials to reduce the rate of neonatal HSV, but even if it only reduces the rate by at least 2% it would be cost-effective in this population.
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